spacer
home > ict > autumn 2009 > solutions central
PUBLICATIONS
International Clinical Trials

Solutions Central

 

TODAY’S CHALLENGE

Over the past 20 years or so, the pharmaceutical service industry has witnessed dramatic changes in the complexity of the compounds being developed and investigated. Along with this complexity came the rationalisation of resources and core competencies in the large and not-solarge pharmas and biotechs, increasing the need for outsourcing the development of speciality assays and biomarkers. With the rapid evolution of molecular biology, immunology and genetic science, finding a competent laboratory with the qualifications and experience to meet the R&D objectives for preclinical and clinical development is a challenge for most drug developers. During the current period of intense change, demand is also increasing due to mergers and acquisitions and the subsequent rationalisation of staffing to meet the economic objectives of the M&A. Conservation of cash by others is resulting in staff reductions and more and more outsourcing to speciality houses that provide the required expertise.

Once the decision to outsource has been taken, a number of additional steps must be considered. A general process would be to identify the types of assays needed (safety assessments, biomarkers, esoteric assays), build a relationship with an appropriate central laboratory that has the capacity to manage your R&D project, negotiate the project parameters so that communication and expectations are clear, and maintain clear communication channels throughout the project to help ensure success in its development.

TODAY’S ENVIRONMENT

Biomarkers and speciality or esoteric assays are today playing an increasingly important role across the clinical development spectrum. From large molecule pharmacokinetic assays and immunogenicity assays, to mutational analysis for subject selection to primary, secondary and exploratory endpoints, biomarker and speciality assays have become critical components in every phase of development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Fraser R Day is a Canadian pharmacist with more than 40 years’ experience in the pharmaceutical, preclinical and clinical trial industries. He has held various strategic sales, marketing and business development positions in all three sectors, including senior management responsibilities on an international scale. Currently Fraser holds the position of Vice- President, Business Development, at CIRION Clinical Trial Services, a Contract R&D and central laboratory in Canada.
spacer
Fraser R Day
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology collaborates with Emerson for new Life Sciences R&D solution: V-Control

Applikon Biotechnology has launched V-Control for R&D scale bioreactors, a sophisticated automation solution developed in collaboration with Emerson. It uses a scaled version of Emerson’s DeltaV distributed control system (DCS), DeltaV Discovery, designed for research and discovery laboratories. V-Control enables easy process control and data up-scaling in one platform. Furthermore, it provides organizations that already use the DeltaV DCS at production scale with reliable automation scaled to fit the needs of the laboratory environment, making tech transfer easier.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement